FindTrial
Sign In

Clinical trial to determine safety and efficacy of intravenous silver nanoparticles in severe covid patients

Assessing Efficacy and Applicability of Intravenous Water Dissolved Silver Nanoparticles as a Novel Adjuvant in the Treatment of Severe SARS CoV2 Identified Pneumonia in Elderly patients ââ?¬â?? An Investigator Initiated Study (IIS).

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/09/036781
Enrollment
40
Registered
2021-09-23
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Intravenous Silver Nanoparticles- AgSept manufactured by BHS medical solutions GmbH Germany) in addition to standard therapy: Treatment duration is 5 days. Control Intervention1: Standa

Sponsors

Dr Subhasish Sarkar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. RT-PCR Confirmed COVID 19 patients of either sex 2. Age greater than 18 years 3. EWS score 5 and above 4. Clinically diagnosed moderately severe and severe pneumonia 5. Willing to participate in the trial.

Exclusion criteria

Exclusion criteria: 1. Patients with EWS score below 5 2. Not Willing to participate in the trial

Design outcomes

Primary

MeasureTime frame
Determining the efficacy of intravenous Silver Nanoparticles (AgSept) in addition to standard therapy for treating moderately severe and severe COVID pneumonia patients with or without co-morbidities of elderly age group in terms of hemodynamic stability, oxygen requirement, duration of hospital stay and mortality prevention.Timepoint: Day 1, Day 3, Day 5 and Day 10—

Secondary

MeasureTime frame
Assessment of Silver Nanoparticles (AgSept) related changes in clinical findings (pulse, Blood Pressure, oxygen saturation, respiration rate, pallor, jaundice and cyanosis), the blood parameters and any serious and non-serious adverse effects immediately after its administration or later in the course of the treatment in moderately severe and severe COVID patients.Timepoint: Day 1, Day 3, Day 5 and Day 10—

Countries

India

Contacts

Public ContactDr Subhasish Sarkar

College of Medicine and Sagore Dutta Hospital

s.sarkar735@gmail.com9564524882

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026